Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Carisma Therapeutics (CARM)
NASDAQ:CARM
RESEARCH TOOLSreports
Carisma Therapeutics (CARM) Stock Price & Analysis
1,507 Followers
CARM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.99 - $8.59
Previous Close$1.1
Volume233.48K
Average Volume (3M)813.12K
Market Cap
$44.24M
Enterprise Value-$28.78M
Total Cash (Recent Filing)$77.61M
Total Debt (Recent Filing)$3.12M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Aug 08, 2024EPS Estimate
-$0.3Last Dividend Ex-Date
Mar 08, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding41,542,744
10 Day Avg. Volume201,349
30 Day Avg. Volume813,123
Standard Deviation0.29
R-Squared0.06
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.60
Price to Sales (P/S)9.88
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.93
Enterprise Value/Gross Profit-0.31
Enterprise Value/Ebitda0.47
Forecast
1Y Price Target
$7.60Price Target Upside613.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Carisma Therapeutics News
PremiumCompany Announcements
Carisma Therapeutics Board Changes and New Compensation Plans
PremiumCompany Announcements
Carisma Therapeutics Grants Executive Stock Options for Retention
Bulls Say, Bears Say
Bulls Say
Collaborative InnovationThis collaboration leverages the technology platforms of both companies, integrating Carisma's CAR-M platform with Moderna's mRNA and lipid nanoparticle technologies to generate in vivo CAR-M therapies to treat various cancers.
Partnership And Milestone PaymentsCarisma is eligible to receive up to $3 billion in milestone and royalty payments from partnered programs.
Regulatory DesignationCT-0525 was granted Fast Track Designation by the FDA, enabling closer interactions and potential benefits for regulatory timelines.
Bears Say
Clinical TrialsTwo patients experienced progressive disease and one patient achieved stable disease in the CT-0508 + Keytruda Phase 1 sub-study.
Financial PerformanceCARM reported 1Q24 results with a net loss of ($19MM).
Product StrategyCarisma recently de-prioritized CT-0508 in favor of CT-0525.
---
Ownership Overview
61.91%
Insiders
6.42% Mutual Funds
3.68% Other Institutional Investors
27.99% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CARM FAQ
What was Carisma Therapeutics’s price range in the past 12 months?
Carisma Therapeutics lowest stock price was $0.99 and its highest was $8.59 in the past 12 months.
What is Carisma Therapeutics’s market cap?
Currently, no data Available
When is Carisma Therapeutics’s upcoming earnings report date?
Carisma Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were Carisma Therapeutics’s earnings last quarter?
Currently, no data Available
Is Carisma Therapeutics overvalued?
According to Wall Street analysts Carisma Therapeutics’s price is currently Undervalued.
Does Carisma Therapeutics pay dividends?
Carisma Therapeutics pays a Notavailable dividend of $0.36 which represents an annual dividend yield of N/A. See more information on Carisma Therapeutics dividends here
What is Carisma Therapeutics’s EPS estimate?
Carisma Therapeutics’s EPS estimate is -$0.3.
How many shares outstanding does Carisma Therapeutics have?
Carisma Therapeutics has 41,542,744 shares outstanding.
What happened to Carisma Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Carisma Therapeutics?
Among the largest hedge funds holding Carisma Therapeutics’s share is Hussman Strategic Advisors Inc. It holds Carisma Therapeutics’s shares valued at N/A.
---
Carisma Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.60 (613.62% Upside)
$7.60 (613.62% Upside)
Blogger Sentiment
Bullish
CARM Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 5.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 12.9%
Last 30 Days ▲ 12.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.99%
12-Months-Change
Fundamentals
Return on Equity
-167.51%
Trailing 12-Months
Asset Growth
-52.74%
Trailing 12-Months
Company Description
Carisma Therapeutics
Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.
---
CARM Stock 12 Month Forecast
Average Price Target
$7.60
▲(613.62% Upside)
Technical Analysis
Crispr Therapeutics AG
―
Editas Medicine
―
Intellia Therapeutics
―
Sangamo Biosciences
―
Best Analysts Covering CARM
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-53.20%
reiterated a buy rating 21 days ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -53.20% per trade.
---